MBX Biosciences, Inc. Common Stock
NASDAQ:MBXBiotechnology
-$0.64 today
- Market cap
- $2.65B
- Beta
- 0.75
- P/E (TTM)
- -22.0
- EPS (TTM)
- -$1.86
Volume 0.73M
Average 0.65M
MBX Net Receivables
Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.
MBX Biosciences, Inc. Common StockNASDAQ: MBX
Net Receivables · Q3 FY2026 · quarter ended Sep 2026
Net receivables rises 108.7% from a year ago
Net receivables stood at $3.23M at the end of Q3 FY2026, up 108.7% from a year earlier and up 6.2% from the prior quarter. Over 3 fiscal years it compounded at +146.2% a year.
Context
- Net receivables amounted to 0.6% of total assets at the end of Q3 FY2026, up 0.3 pp from a year earlier.
- Net receivables increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether net receivables keeps rising in the next quarterly balance sheet after a +108.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Receivables history
USD · from the balance sheet
- Latest · FY2025
- 2.12M USD
- Year-over-year change
- +210.9%
- 3-year CAGR
- +146.2%
| Period | Period end | Net Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.12M | +210.9% |
| FY2024 | 2024-12-31 | 682K | +227.9% |
| FY2023 | 2023-12-31 | 208K | +46.5% |
| FY2022 | 2022-12-31 | 142K | — |
Net Receivables vs competitors
How MBX compares with its peers on the latest reported figures
- Peers report in different currencies, so net receivables is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +108.7% is the highest of 6, against a peer median of +18.4%.
- Net receivables amounts to 0.6% of total assets for MBX, versus a peer median of 0.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | €242.52M EUR | +64.7% | +136.5% | 10.0% | |
| Mar 2026 | $56.3M USD | +21.5% | +18.3% | 14.4% | |
| Sep 2026 | $39.12M USD | +18.4% | +61.2% | 8.8% | |
MBXMBX Biosciences, Inc. Common Stock | Sep 2026 | $3.23M USD | +108.7% | +146.2% | 0.6% |
| Mar 2026 | $1.67M USD | -32.4% | -11.9% | 0.5% | |
| Jun 2026 | $0 USD | — | — | 0.0% | |
KLRAKailera Therapeutics, Inc. | Jun 2026 | $0 USD | — | — | 0.0% |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Mar 2026 | $0 USD | -100.0% | — | 0.0% | |
| Peer median (excluding MBX) | — | +18.4% | +39.8% | 0.2% | |
Competitors are the stored peer set for MBX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
MBX Biosciences, Inc. Common Stock
NASDAQ:MBX
Intrinsic Alpha fair value
Locked
Current Price
$53.42
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.